If Novartis are stalling maybe a GlaxoSmithKline may come in with a competing offer to do something with MSB.
They worked with Biota on flu therapies previously for example.
At some point big pharma competing with each other to join the fray, and or making competing take over offers, is a very likely development.
Where is Novartis?, page-308
-
- There are more pages in this discussion • 1,209 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
0.020(1.89%) |
Mkt cap ! $1.233B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.06 | $2.442M | 2.263M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 52806 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 16723 | 7 |
View Market Depth
| Last trade - 14.32pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |